Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label caspofungin first-line treatment study in invasive aspergillosis
2004-002944-90Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2005
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of caspofungin in invasive aspergillosis (IA) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Response rate at end of caspofungin therapy. Started Feb 2005; status: completed.
02
Drugs
caspofungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on 2004-002944-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002944-90.